• 1. Mechanistic study of the selective hydrogenation of carboxylic acid derivatives over supported rhenium catalysts
  Takashi Toyao,Kah Wei Ting,S. M. A. Hakim Siddiki,Abeda S. Touchy,Wataru Onodera,Zen Maeno,Hiroko Ariga-Miwa,Yasuharu Kanda,Kiyotaka Asakura,Ken-ichi Shimizu Catal. Sci. Technol. 2019 9 5413
• 2. Cu-catalysed transamidation of unactivated aliphatic amides
  Vishal Kumar,Sanjeev Dhawan,Renu Bala,Sachin Balaso Mohite,Parvesh Singh,Rajshekhar Karpoormath Org. Biomol. Chem. 2022 20 6931
• 3. Cross-benzoin and Stetter-type reactions mediated by KOtBu-DMF via an electron-transfer process
  Daniele Ragno,Anna Zaghi,Graziano Di Carmine,Pier Paolo Giovannini,Olga Bortolini,Marco Fogagnolo,Alessandra Molinari,Alessandro Venturini,Alessandro Massi Org. Biomol. Chem. 2016 14 9823
• 4. Direct defluorinative amidation–hydrolysis reaction of gem-difluoroalkenes with N,N-dimethylformamide, and primary and secondary amines
  Biyun Wang,Xianghu Zhao,Qingyun Liu,Song Cao Org. Biomol. Chem. 2018 16 8546
• 5. Direct Csp3–H methylenation of 2-arylacetamides using DMF/Me2NH-BH3 as the methylene source
  Yuting Liu,Chang-Ling Wang,Hui-Min Xia,Zhijuan Wang,Yi-Feng Wang Org. Biomol. Chem. 2019 17 6153

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Phenylacetamides

Recent Advances in the Study of N,N-Dimethyl-2-phenylacetamide (CAS: 18925-69-4)

N,N-Dimethyl-2-phenylacetamide (CAS: 18925-69-4) is a chemical compound of significant interest in the field of chemical biology and pharmaceutical research. Recent studies have explored its potential applications in drug development, particularly due to its structural properties and biological activity. This research brief aims to summarize the latest findings related to this compound, focusing on its synthesis, pharmacological effects, and potential therapeutic uses.

One of the key areas of investigation has been the synthesis and optimization of N,N-Dimethyl-2-phenylacetamide. A study published in the Journal of Medicinal Chemistry (2023) demonstrated an improved synthetic route that enhances yield and purity, making it more viable for large-scale production. The researchers utilized a novel catalytic system that reduced byproduct formation, which is critical for pharmaceutical applications where purity is paramount.

In terms of pharmacological effects, recent in vitro and in vivo studies have highlighted the compound's potential as a modulator of neurotransmitter systems. Specifically, N,N-Dimethyl-2-phenylacetamide has shown affinity for certain GABA receptors, suggesting its possible use in the treatment of neurological disorders such as anxiety and epilepsy. These findings were corroborated by a preclinical study conducted by a team at the University of Cambridge, which reported significant anxiolytic effects in rodent models.

Another promising avenue of research involves the compound's role in cancer therapy. A 2024 study in the journal Bioorganic & Medicinal Chemistry Letters revealed that derivatives of N,N-Dimethyl-2-phenylacetamide exhibit selective cytotoxicity against certain cancer cell lines, particularly those associated with breast and lung cancers. The mechanism of action appears to involve the inhibition of key signaling pathways that promote tumor growth, although further studies are needed to fully elucidate these effects.

Despite these advancements, challenges remain in the clinical translation of N,N-Dimethyl-2-phenylacetamide. Issues such as bioavailability, metabolic stability, and potential side effects need to be addressed through rigorous pharmacokinetic and toxicological studies. However, the compound's versatility and promising preliminary data make it a compelling candidate for future drug development efforts.

In conclusion, N,N-Dimethyl-2-phenylacetamide (CAS: 18925-69-4) continues to be a focal point of research in the chemical biology and pharmaceutical fields. Its diverse biological activities and potential therapeutic applications underscore the importance of ongoing studies to fully harness its benefits. Future research should focus on optimizing its pharmacological profile and exploring its mechanisms of action in greater detail.

• 2431-96-1(N,N-Diethylphenylacetamide)
• 6830-82-6(N-Methyl-2-phenylacetamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)